Abstract
In this issue of Cell Stem Cell, Xu etal. (2019) demonstrate that editing iPSCs' major histocompatibility antigens may potentially provide a small set of universally compatible stem cell lines for therapies. However, these modifications may result in patient minor histocompatibility responses and deficiencies in their Tcell response repertoire to infection and cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have